SCHEMBL29367441

SCHEMBL29367441

Nc1ccnc2nc[nH]c12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PI4KA P42356 2/20 0.50
PI4K2B Q8TCG2 2/20 0.50
PI4K2A Q9BTU6 2/20 0.50
PI4KB Q9UBF8 2/20 0.50
LRRK2 Q5S007 2/20 0.50
LMNA P02545 1/20 0.50
DRD3 P35462 1/20 0.50
XDH P47989 1/20 0.50
ALDH1A1 P00352 1/20 0.46
BRD4 O60885 3/20 0.44
PDPK1 O15530 2/20 0.44
GDA Q9Y2T3 1/20 0.44
CYP3A4 P08684 2/20 0.42
CDK2 P24941 2/20 0.41
DPP4 P27487 1/20 0.41
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
PNP P00491 1/20 0.40
G6PD P11413 1/20 0.39
MAP3K5 Q99683 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7108989 1.00 PI4KA (0.50) PI4KAPI4K2BPI4K2API4KBLRRK2
SCHEMBL30838803 0.98 PI4KA (0.48) PI4KAPI4K2BPI4K2API4KBLRRK2
SCHEMBL3974202 0.74 ALDH1A1 (0.46) PI4KAPI4K2BPI4K2API4KBLRRK2
SCHEMBL22830483 0.74 ALDH1A1 (0.46) PI4KAPI4K2BPI4K2API4KBLRRK2
SCHEMBL30788403 0.74 ALDH1A1 (0.46) PI4KAPI4K2BPI4K2API4KBLRRK2
SCHEMBL19778900 0.74 ALDH1A1 (0.46) PI4KAPI4K2BPI4K2API4KBLRRK2
SCHEMBL323982 0.74 ALDH1A1 (0.52) PI4KAPI4K2BPI4K2API4KBLRRK2
SCHEMBL2493987 0.74 BRD4 (0.51) PI4KAPI4K2BPI4K2API4KBLRRK2
SCHEMBL1165562 0.74 ALDH1A1 (0.46) PI4KAPI4K2BPI4K2API4KBLRRK2
SCHEMBL29804946 0.74 ALDH1A1 (0.46) PI4KAPI4K2BPI4K2API4KBLRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1427 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4677110-A1 IMPROVED METHOD FOR DETECTING A TARGET VARIANT BASE USING A VARIANT-SPECIFIC PROBE Rarity Bioscience AB (SE) 2026-01-14 EP claimed
EP-3833715-B1 SILICON-SUBSTITUTED RHODAMINE DYES AND DYE CONJUGATES LIFE TECHNOLOGIES CORP (US) 2026-01-07 EP claimed
US-20250320177-A1 COMPOUNDS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS HONGENE BIOTECH CORP (US) 2025-10-16 US claimed
CN-119998357-A Compositions and methods for liquid phase oligonucleotide synthesis 兆维生物科技公司 2025-05-13 CN claimed
EP-4543960-A1 COMPOSITIONS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS Hongene Biotech Corporation (US) 2025-04-30 EP claimed
WO-2025081542-A1 GRNA AND BIOSYNTHESIS METHOD THEREFOR 吉林凯莱英医药化学有限公司 2025-04-24 WO claimed
WO-2025081543-A1 RNA CONTAINING PHOSPHOROTHIOATE BOND AND PREPARATION METHOD THEREFOR 吉林凯莱英医药化学有限公司 2025-04-24 WO claimed
WO-2025081539-A1 TRNA AND BIOSYNTHESIS METHOD THEREFOR 吉林凯莱英医药化学有限公司 2025-04-24 WO claimed
WO-2025081541-A1 PREPARATION METHOD FOR NON-NATURAL RNA AND PRODUCT 吉林凯莱英医药化学有限公司 2025-04-24 WO claimed
CN-119462803-B Nucleoside monomer analogue, oligonucleotide synthesis method and application 天津凯莱英生物科技有限公司 2025-04-18 CN claimed
CN-116903690-A Nucleoside dimer, preparation method thereof and application thereof in DNA synthesis 中国人民解放军军事科学院军事医学研究院 2023-10-20 CN claimed
US-11725073-B2 Compositions and methods for liquid phase oligonucleotide synthesis HONGENE BIOTECH CORPORATION (US) 2023-08-15 US claimed
US-20230212209-A1 COMPOSITIONS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS HONGENE BIOTECH CORPORATION 2023-07-06 US claimed
CN-109661232-B Nucleotide derivatives and methods of use thereof 纽约哥伦比亚大学董事会 2023-03-03 CN claimed
US-20230028321-A1 NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-01-26 US claimed
US-20230028388-A1 DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-01-26 US claimed
US-20220411860-A1 DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2022-12-29 US claimed
US-20220298201-A1 FLUORINATED NUCLEOTIDES AND USES THEREOF FIRST-CITIZENS BANK & TRUST COMPANY 2022-09-22 US claimed
US-20220204670-A1 COMPOSITIONS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS HONGENE BIOTECH CORPORATION 2022-06-30 US claimed
CN-108779138-B Design and synthesis of nucleotides based on novel disulfide linkers for use as reversible terminators for DNA sequencing by synthesis 哥伦比亚大学董事会 2022-06-17 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250320177-A1 COMPOUNDS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS POLR2H, POLRMT, POLR2E PI4KA 2006/4885PI4K2B 2227/4885PI4K2A 2210/4885
US-20230212209-A1 COMPOSITIONS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS POLR2H, POLR2E, POLI PI4KA 894/4885PI4K2B 1183/4885PI4K2A 1200/4885
US-20220411860-A1 DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS POLL, POLQ, POLB PI4KA 1619/4885PI4K2B 1385/4885PI4K2A 1499/4885
US-20230028388-A1 DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS RNGTT, POLRMT, MTR PI4KA 3406/4885PI4K2B 2863/4885PI4K2A 2484/4885
US-11725073-B2 Compositions and methods for liquid phase oligonucleotide synthesis RNGTT, POLR2H, POLI PI4KA 1133/4885PI4K2B 1640/4885PI4K2A 1374/4885
US-20220204670-A1 COMPOSITIONS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS RNGTT, POLR2H, POLI PI4KA 1133/4885PI4K2B 1640/4885PI4K2A 1374/4885
US-20220298201-A1 FLUORINATED NUCLEOTIDES AND USES THEREOF NOP2, FBL, RNGTT PI4KA 1367/4885PI4K2B 1831/4885PI4K2A 1619/4885
US-20230028321-A1 NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF POLRMT, NSUN2, NUDT1 PI4KA 1550/4885PI4K2B 1844/4885PI4K2A 1621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.